BOULDER — Array Biopharma Inc. (Nasdaq: ARRY) beat analyst expectations for its third quarter earnings by 11 cents, despite posting a loss of 11 cents per share.
Array, a Boulder-based biotech company, had a net loss of nearly $22.9 million, an improvement on the same period the year prior, when the net loss was $35.3 million.
Revenue was $66 million, which grew 99 percent year-over-year and beat expectations by $34.7 million.
Array added that its new drug applications for the combination of its drugs encorafenib and binimetinib to treat patients with advanced or metastatic melanoma are under review with a target action date of June 30.
First Bank – Making Your Business Big
BizWest TV Leadership Series – Adrian Tuck – Tendril
BizWest TV Leadership Series – Lou DellaCava – LJD Enterprises
BizWest TV Leadership Series – Frank Day – Boulderado
BizWest TV Leadership Series – Curt Richardson – OtterBox
BizWest TV Leadership Series – Richard Bisson – Waterpik
